Evidence map›Paper›PMID 41240092›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Normal organ [

Hind Ait Talhiq, Philippe Baltzinger, Juliette Frega, Cedric Collen, Maximilien Colin Valentin, Gabriel G Malouf, Clemence Porot, Meher Ben Abdelghani, Pietro Addeo, Bernard Goichot and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hind Ait TalhiqNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Philippe BaltzingerEndocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Juliette FregaNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Cedric CollenEndocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Maximilien Colin ValentinNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Gabriel G MaloufInstitut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Clemence PorotInstitut de Cancérologie Strasbourg Europe (ICANS), Radiopharmacy, Strasbourg, France.
Meher Ben AbdelghaniInstitut de Cancérologie Strasbourg Europe (ICANS), Gastroenterology, Strasbourg, France.
Pietro AddeoHepato-Pancreato-Biliary Surgery and Liver Transplantation, University Hospitals of Strasbourg, Strasbourg, France.
Bernard GoichotEndocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Valentina BertiDepartment of Experimental and Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy.
Alessio ImperialeNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France. a.imperiale@icans.eu.ORCID 0000-0003-2751-5146

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo characterize longitudinal changes in normal-organ [

methodsThirty-four patients who underwent [

resultsThe most significant, consistent changes occurred in the liver and spleen, both of which significantly increased from PET-baseline to PET-interim and further to PET-end (liver: +61%, spleen: +103%, p < 0.01) and evolved in parallel (r = 0.64-0.71). Hepatic uptake continued to rise through the end of PRRT and remained elevated long after the last SSA injection. At interim, liver SUVmax was higher in early PET responders than in non-responders and in patients who later progressed at one year; the spleen showed a similar pattern. These findings suggest an SSA-timing-sensitive background drift superimposed on treatment effects.

conclusionNormal organ [

Indexed as

Intestinal NeoplasmsNeuroendocrine TumorsOctreotideOrganometallic CompoundsSomatostatinAdultAgedBiological TransportFemaleHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesGa(III)-DOTATOCOctreotideOrganometallic CompoundsRadiopharmaceuticalsSomatostatin[177Lu]DOTATATE[68Ga]DOTATOCNeuroendocrineNormal organPeptide receptor radionuclide therapy

Identifiers

PMID41240092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.